Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Non-alcoholic Fatty Liver Disease | 6 | 2020 | 907 | 2.17 | Why? |
| Hepatitis B, Chronic | 4 | 2020 | 616 | 1.34 | Why? |
| Acute-On-Chronic Liver Failure | 4 | 2020 | 237 | 1.10 | Why? |
| Hepatitis C, Chronic | 3 | 2017 | 973 | 1.04 | Why? |
| Fatty Liver | 2 | 2020 | 299 | 0.76 | Why? |
| Liver Diseases | 3 | 2020 | 2698 | 0.61 | Why? |
| Metabolic Diseases | 1 | 2020 | 505 | 0.57 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.56 | Why? |
| Liver Cirrhosis | 3 | 2020 | 1810 | 0.53 | Why? |
| Virus Activation | 1 | 2017 | 480 | 0.48 | Why? |
| Diabetes Complications | 1 | 2020 | 2358 | 0.36 | Why? |
| Liver Transplantation | 3 | 2020 | 2864 | 0.35 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.33 | Why? |
| Hepatitis B virus | 3 | 2017 | 882 | 0.30 | Why? |
| Antiviral Agents | 4 | 2020 | 41703 | 0.22 | Why? |
| Obesity | 1 | 2020 | 7388 | 0.20 | Why? |
| Liver Function Tests | 3 | 2020 | 1325 | 0.19 | Why? |
| Carcinoma, Hepatocellular | 2 | 2020 | 1222 | 0.19 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.18 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.18 | Why? |
| Immunosuppressive Agents | 1 | 2017 | 6331 | 0.18 | Why? |
| Peptide Hormones | 1 | 2017 | 14 | 0.17 | Why? |
| Angiopoietin-like Proteins | 1 | 2017 | 16 | 0.17 | Why? |
| Liver Neoplasms | 2 | 2020 | 1666 | 0.17 | Why? |
| Fibroblast Growth Factors | 1 | 2017 | 119 | 0.16 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.16 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.16 | Why? |
| Coronavirus Infections | 8 | 2020 | 253789 | 0.16 | Why? |
| Guanine | 1 | 2017 | 146 | 0.15 | Why? |
| Sustained Virologic Response | 1 | 2017 | 378 | 0.15 | Why? |
| Cost Savings | 1 | 2017 | 296 | 0.14 | Why? |
| Intra-Abdominal Fat | 1 | 2017 | 227 | 0.14 | Why? |
| Disease Progression | 4 | 2020 | 13580 | 0.14 | Why? |
| Drug Costs | 1 | 2017 | 313 | 0.13 | Why? |
| Drug Therapy, Combination | 2 | 2017 | 7268 | 0.13 | Why? |
| Tenofovir | 1 | 2017 | 449 | 0.13 | Why? |
| Metabolic Syndrome | 1 | 2020 | 810 | 0.12 | Why? |
| Pandemics | 9 | 2020 | 389249 | 0.12 | Why? |
| Public Health | 1 | 2017 | 16359 | 0.11 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.10 | Why? |
| Humans | 23 | 2021 | 930598 | 0.10 | Why? |
| Decision Support Techniques | 1 | 2017 | 903 | 0.10 | Why? |
| Chromosomes, Human, Pair 6 | 1 | 2009 | 14 | 0.10 | Why? |
| Alkyl and Aryl Transferases | 1 | 2009 | 22 | 0.10 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.10 | Why? |
| Genes, Tumor Suppressor | 1 | 2009 | 43 | 0.10 | Why? |
| Patient Selection | 2 | 2020 | 4560 | 0.09 | Why? |
| Interferon-alpha | 1 | 2017 | 1442 | 0.09 | Why? |
| Medication Adherence | 1 | 2017 | 1270 | 0.09 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.08 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.08 | Why? |
| Ultrasonography | 2 | 2020 | 4409 | 0.08 | Why? |
| Risk Factors | 6 | 2020 | 71621 | 0.08 | Why? |
| Drug Discovery | 1 | 2020 | 3092 | 0.08 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.08 | Why? |
| Liver | 1 | 2020 | 4007 | 0.07 | Why? |
| China | 3 | 2020 | 50654 | 0.07 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.07 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.07 | Why? |
| Societies, Medical | 1 | 2020 | 6907 | 0.06 | Why? |
| Nomograms | 2 | 2020 | 790 | 0.06 | Why? |
| Prognosis | 4 | 2020 | 32490 | 0.06 | Why? |
| Asia | 2 | 2020 | 2399 | 0.06 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.05 | Why? |
| Follow-Up Studies | 1 | 2020 | 17020 | 0.05 | Why? |
| Treatment Outcome | 2 | 2017 | 51732 | 0.05 | Why? |
| Male | 9 | 2020 | 367725 | 0.05 | Why? |
| Female | 9 | 2020 | 380317 | 0.05 | Why? |
| Biomarkers | 3 | 2017 | 23361 | 0.05 | Why? |
| Middle Aged | 8 | 2020 | 270681 | 0.05 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.05 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.05 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2020 | 5440 | 0.04 | Why? |
| Melanoma | 1 | 2009 | 1229 | 0.04 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 6653 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.04 | Why? |
| Acute Kidney Injury | 1 | 2017 | 5762 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Skin Neoplasms | 1 | 2009 | 1679 | 0.04 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Adult | 5 | 2020 | 244371 | 0.03 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Chromosome Breakage | 1 | 2009 | 2 | 0.03 | Why? |
| Neoplasm Transplantation | 1 | 2009 | 55 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Mice, Nude | 1 | 2009 | 340 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2020 | 6543 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Multiple Organ Failure | 1 | 2017 | 1724 | 0.02 | Why? |
| Aged | 2 | 2020 | 215776 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Consensus | 1 | 2020 | 6345 | 0.02 | Why? |
| Diet | 1 | 2017 | 2052 | 0.02 | Why? |
| Molecular Sequence Data | 1 | 2009 | 3198 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.02 | Why? |
| Down-Regulation | 1 | 2009 | 1416 | 0.02 | Why? |
| Prospective Studies | 2 | 2017 | 43301 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Immunity, Innate | 1 | 2020 | 6570 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2020 | 4927 | 0.01 | Why? |
| Base Sequence | 1 | 2009 | 3581 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2017 | 11304 | 0.01 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
| Cell Line, Tumor | 1 | 2009 | 3608 | 0.01 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2017 | 25144 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |
| Mice | 1 | 2009 | 21357 | 0.01 | Why? |
| Animals | 1 | 2009 | 78931 | 0.00 | Why? |
Lau's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(117)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(99)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_